{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T23:03:35Z","timestamp":1774739015838,"version":"3.50.1"},"reference-count":72,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Danish Regions"},{"name":"the Health Science Research Fund of the North Denmark Region"},{"name":"Department of Rheumatology at Aalborg University Hospital"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,6,14]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA). Traditionally, these patients maintain standard dosage of bDMARD lifelong; however, recent studies indicate that a significant proportion of patients in sustained remission or LDA can taper their bDMARD and maintain stable disease activity. Thus, this trial aims to evaluate whether a disease activity-guided tapering strategy for bDMARDs will enable a significant dosage reduction while maintaining disease activity compared with usual care. From the individual patient\u2019s standpoint as well as from a societal perspective, it would be advantageous if bDMARDs could be reduced or even discontinued while maintaining disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A total of 180 patients with RA, PsA or axSpA treated with bDMARDs and in clinical remission\/LDA during the past 12 months will be enrolled from four centres in Denmark. Patients will be randomised in a ratio of 2:1 to either disease activity-guided tapering of bDMARDs (intervention group) or continuation of bDMARDs as usual care (control group).<\/jats:p>\n                    <jats:p>The primary objective is the difference between the two groups in the proportion of patients who have reduced their inclusion dosage of bDMARDs to 50% or less while maintaining stable disease activity at 18 months follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study is approved by the ethics committee of Northern Jutland, Denmark (N-20170073) and by the Danish Medicine Agency. Patient research partner KHH contributed to refinement of the protocol and approved the final manuscript. Results will be disseminated through publication in international peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>2017-001970-41; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-028517","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T06:24:30Z","timestamp":1562739870000},"page":"e028517","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-7175","authenticated-orcid":false,"given":"Line","family":"Uhrenholt","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Schlemmer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen-Margrethe","family":"Hauge","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[{"name":"Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"},{"name":"Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salome","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"key":"2025121400144585000_9.7.e028517.1","first-page":"CD012183","article-title":"Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease modifying anti-rheumatic drugs: a systematic review and network meta-analysis","volume":"5","author":"Singh","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400144585000_9.7.e028517.2","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400144585000_9.7.e028517.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025121400144585000_9.7.e028517.4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2025121400144585000_9.7.e028517.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201"},{"key":"2025121400144585000_9.7.e028517.7","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2025121400144585000_9.7.e028517.9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol Int"},{"key":"2025121400144585000_9.7.e028517.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025121400144585000_9.7.e028517.11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025121400144585000_9.7.e028517.13","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2016","author":"Singh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025121400144585000_9.7.e028517.15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22708","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025121400144585000_9.7.e028517.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212423"},{"key":"2025121400144585000_9.7.e028517.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141520"},{"key":"2025121400144585000_9.7.e028517.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew033"},{"key":"2025121400144585000_9.7.e028517.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2886-1"},{"key":"2025121400144585000_9.7.e028517.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204229"},{"key":"2025121400144585000_9.7.e028517.21","first-page":"145","article-title":"Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab","volume":"23","author":"Covelli","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400144585000_9.7.e028517.22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025121400144585000_9.7.e028517.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2025121400144585000_9.7.e028517.24","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians' perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology"},{"key":"2025121400144585000_9.7.e028517.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209201"},{"key":"2025121400144585000_9.7.e028517.26","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015599446"},{"key":"2025121400144585000_9.7.e028517.27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/RHU.0000000000000617","article-title":"Low doses of etanercept can be effective to maintain remission in psoriatic arthritis patients","volume":"24","author":"de Stefano","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025121400144585000_9.7.e028517.28","first-page":"201","article-title":"Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study","volume":"6","author":"Cantini","year":"2012","journal-title":"Biologics"},{"key":"2025121400144585000_9.7.e028517.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew269"},{"key":"2025121400144585000_9.7.e028517.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1389"},{"key":"2025121400144585000_9.7.e028517.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211169"},{"key":"2025121400144585000_9.7.e028517.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206696"},{"key":"2025121400144585000_9.7.e028517.33","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"2025121400144585000_9.7.e028517.34","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400144585000_9.7.e028517.35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00296-015-3288-z","article-title":"Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity?","volume":"35","author":"Almirall","year":"2015","journal-title":"Rheumatol Int"},{"key":"2025121400144585000_9.7.e028517.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135129"},{"key":"2025121400144585000_9.7.e028517.37","first-page":"1580","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism Collaborative initiative","volume":"2010","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025121400144585000_9.7.e028517.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025121400144585000_9.7.e028517.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025121400144585000_9.7.e028517.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025121400144585000_9.7.e028517.42","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(73)90035-8"},{"key":"2025121400144585000_9.7.e028517.43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh297"},{"key":"2025121400144585000_9.7.e028517.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025121400144585000_9.7.e028517.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025121400144585000_9.7.e028517.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025121400144585000_9.7.e028517.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2025121400144585000_9.7.e028517.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00091-2"},{"key":"2025121400144585000_9.7.e028517.49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3750"},{"key":"2025121400144585000_9.7.e028517.50","doi-asserted-by":"publisher","DOI":"10.1186\/ar4145"},{"key":"2025121400144585000_9.7.e028517.51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"},{"key":"2025121400144585000_9.7.e028517.52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.87802"},{"key":"2025121400144585000_9.7.e028517.53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005297","article-title":"Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol","volume":"4","author":"Dossing","year":"2014","journal-title":"BMJ Open"},{"key":"2025121400144585000_9.7.e028517.54","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMra1709701","article-title":"Multiplicity considerations in clinical trials","volume":"378","author":"Dmitrienko","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121400144585000_9.7.e028517.55","first-page":"63","article-title":"Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose","volume":"33","author":"Raffeiner","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400144585000_9.7.e028517.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205726"},{"key":"2025121400144585000_9.7.e028517.57","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2839-4"},{"key":"2025121400144585000_9.7.e028517.58","first-page":"872","article-title":"Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice","volume":"34","author":"Rodriguez-Rodriguez","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400144585000_9.7.e028517.59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200945"},{"key":"2025121400144585000_9.7.e028517.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61704-9"},{"key":"2025121400144585000_9.7.e028517.61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.39946","article-title":"Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review","volume":"69","author":"Tweehuysen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121400144585000_9.7.e028517.62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212178"},{"key":"2025121400144585000_9.7.e028517.63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202281"},{"key":"2025121400144585000_9.7.e028517.64","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"2025121400144585000_9.7.e028517.65","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe","year":"1996","journal-title":"J Rheumatol"},{"key":"2025121400144585000_9.7.e028517.66","doi-asserted-by":"publisher","DOI":"10.1080\/03009740151095402"},{"key":"2025121400144585000_9.7.e028517.67","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025121400144585000_9.7.e028517.68","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2025121400144585000_9.7.e028517.69","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"2025121400144585000_9.7.e028517.70","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2025121400144585000_9.7.e028517.71","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"2025121400144585000_9.7.e028517.72","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-028517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:14:56Z","timestamp":1765700096000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-028517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":72,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,9]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bmjopen-2018-028517"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-028517","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}